Cochlear Limited

The Business

Cochlear makes and sells surgically implanted hearing devices, split across three divisions: Cochlear Implants (the surgical device itself, roughly 61% of revenue), Services (processor upgrades and support for existing recipients, roughly 27%), and Acoustics (bone conduction hearing solutions, roughly 12%). The Implants division drives new patient growth; Services is the annuity, monetising an installed base that grows every year regardless of new implant volumes. This mix, one growth engine and one compounding annuity, is what differentiates Cochlear from single-product medtech peers.

Recent Performance

FY26 revenue fell 0.6% to $2,343 million, reversing FY25's 4.3% growth, and earnings per share dropped 20% to $4.97. The culprits were currency translation, one-off cloud transition and restructuring costs, and a fourth consecutive year of decelerating constant-currency growth in adult cochlear implant demand. Gross margin compressed from 73.9% to 70.7% over the same period, a meaningful step down for a business known for pricing power.

Outlook

Revenue growth is expected to reaccelerate over the following two to three years as one-off costs roll off and restructuring savings land, with EBITDA margin recovering from FY26's trough but likely remaining below the FY25 peak of 27.2% through the forecast horizon. Earnings per share is expected to rebound over the same period, though not in a straight line. The key swing factor is whether adult referral growth genuinely reaccelerates or merely stabilises at a lower structural rate, a distinction that matters more to the outlook than any single year's result.

Key Risks

Adult referral growth may be structurally, not just cyclically, slower. Only around 40% of US cochlear implant referrals currently come through medical channels rather than consumer-driven demand, and constant-currency growth has decelerated for four consecutive years. If pilot programs expanding the medical referral pathway fail to scale beyond a handful of cities, the growth reacceleration built into the outlook does not materialise. A further appreciation in the Australian dollar against Cochlear's largely offshore revenue base is a second material risk, since more than 90% of revenue is earned outside Australia while hedging covers only a 12-month window. Third, Chinese volume-based pricing spreading to other emerging markets could permanently cap gross margin below its historical range, an outcome management has not yet demonstrated it can prevent outside China.

What to Watch

• FY28 US ENT pilot expansion (4 to 12 cities) — the thesis-defining event; confirms whether medicalisation of adult referrals can scale beyond a handful of pilot markets.
• Feb 2027 FY27 half-year results — first real evidence of the margin recovery built into the outlook.
• FY28-29 TICI pivotal study interim data — a longer-dated, binary catalyst for category expansion, not currently assumed in the base outlook.

Company Description

Cochlear operates three divisions. Cochlear Implants, the surgical device business, generated roughly $1,435 million in FY26 (61% of revenue) and drives new-patient volume growth. Services, covering sound processor upgrades and clinical support for the existing recipient base, generated $635 million (27%) and is the most predictable part of the business. Acoustics, the bone conduction hearing device line acquired partly through the Demant transaction, contributed $273 million (12%) after a difficult FY26. The company competes globally against just two other meaningful players, MED-EL and Advanced Bionics (owned by Sonova).

Where the Growth Is

Services is the standout structural growth driver. At 27% of group revenue and growing 5-7% in constant currency annually, it monetises an installed base of over 800,000 recipients who need periodic processor upgrades regardless of how new-implant demand trends. This segment's scale and predictability provide a cushion under the more volatile implant growth story, since it compounds independently of near-term referral trends.

Competitive Position

Cochlear's more than 60% global share has been stable for years, in a three-player market where no new entrant has gained meaningful ground in four decades. The barriers are real: regulatory approval cycles of three to five years, decades of clinical outcome data that cannot be replicated quickly, and a recipient base that faces surgery, not a subscription cancellation, to switch providers. The main competitive pressure point is Germany, where MED-EL has taken share in a market undergoing capacity backlogs. That is a localised issue rather than a broader erosion of Cochlear's position, but it is worth monitoring as evidence of whether the oligopoly is genuinely stable or slowly shifting.

Management & Capital Discipline

Capital allocation has been disciplined: a 70% fully franked dividend payout, zero net debt, a measured acquisition of Demant's cochlear implant business rather than a large transformative deal, and research and development prioritised ahead of M&A. Management took zero incentive payments in FY26, with 0% long-term incentive vesting and no CEO short-term bonus, a rare and credible show of accountability for a soft year. The honest observation is that this alignment has not yet translated into consistent execution on adult referral growth, which has decelerated for four straight years despite years of direct-to-consumer investment.

Financial Position

Cochlear carries no net debt and holds a net cash position, supported by undrawn credit facilities. Free cash flow per share is expected to grow steadily over the coming years as working capital normalises. The balance sheet gives Cochlear the flexibility to fund research and development, maintain its dividend, and pursue opportunistic acquisitions from internally generated cash alone. This is a business that could comfortably absorb a prolonged downturn without financial stress.